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ABSTRACT 
Background & Aims. Advances in direct acting anti-viral treatment of HCV have reinvigorated 
public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of 
only diagnosed and linked-to-care individuals on overall HCV burden estimates and identified a 
possible strategy to achieve the WHO targets by 2030. 
 
Methods. Using a modelling approach grounded in Italian real-life data of diagnosed and treated 
patients, different linkage-to-care scenarios were built to evaluate potential strategies in achieving the 
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Results. Under the 40% linked-to-care scenario, viremic burden would decline (60%); however 
eligible patients to treat will be depleted by 2025. Increased case finding through a targeted screening 
strategy in 1948-1978 birth cohorts could supplement the pool of diagnosed patients by finding 75% 
of F0-F3 cases. Under the 60% linked-to-care scenario, viremic infections would decline by 70% by 
2030 but the patients eligible for treatment will run out by 2028. If treatment is to be maintained, a 
screening strategy focusing on 1958-1978 birth cohorts could capture 55% of F0-F3 individuals. 
Under the 80% linked-to-care scenario, screening limited in 1968-1978 birth cohorts could sustain 
treatment at levels required to achieve the HCV elimination goals. 
 
Conclusion. In Italy, which is an HCV endemic country, the eligible pool of patients to treat will run 
out between 2025 and 2028. To maintain the treatment rate and achieve the HCV elimination goals, 
increased case finding in targeted, high prevalence groups is required. 
 
Key words: HCV; chronic infection; WHO; linkage to care  
 
LAY SUMMARY 
Considering that Hepatitis C has a complex and heterogeneous natural history resulting in differing 
prognoses for infected individuals, it is difficult to estimate the disease burden based only in 
symptomatic patients, in that they represent only a visible part of the iceberg. In Italy, which is a high 
endemic country for HCV infection, considering only linked to care patients, the eligible pool of 
patients to be treated would run out between 2025 and 2028, leaving a significant proportion of 
infected individuals undiagnosed and without access to care.  Increased case finding in general 
population birth cohorts estimated to have higher HCV prevalence, is necessary to achieve the World 
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INTRODUCTION 
Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. An 
estimated 71 million people are affected by chronic hepatitis C (CHC) infection
1
 and a significant 
number of those chronically infected progress to cirrhosis or liver cancer if left untreated.
2-3
 However, 
the development of direct-acting antiviral (DAA) therapy has revolutionized the approach to treatment 
and reinvigorated public health initiatives aimed at identifying patients with CHC. Galvanized by 
these results, the World Health Organization (WHO) foresees the elimination of HCV infection by 
2030 through achieving the Global Health Sector Strategy Goals (GHSS) for Hepatitis
4
. While 
targeted screening programs for high risk populations such as injection drug users are,
5-6
 little has 
been done to understand what increases in diagnosis and treatment are necessary in the general 
population of high endemic countries for achieving these goals. Given that the use of DAAs 
regardless of fibrosis stage is cost-effective,
7
 it is crucial that health policies expand treatment access 
for all HCV infected individuals. The goal of this study was to use a new modelling approach, 
grounded in real-life cohort data of diagnosed and treated patients, to compare different linkage to 
care scenarios to the overall HCV infected population in Italy. We aimed to evaluate the possible 
impact of only linked-to-care individuals on overall HCV burden and to identify a possible strategy to 




Two Markov-disease burden models were developed to assess the current and future HCV disease 
burden in Italy. The ‘Italy Polaris’ model is grounded in the natural history of HCV progression and 
forecasts the HCV impact on the general population. A similar HCV disease burden model, grounded 
in the current distribution of linked-to-care patients of the PITER (Italian Platform for the Study of 
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PITER cohort  
PITER is an ongoing cohort of 9,145 consecutively enrolled patients from 90 public, general hospitals 
and university medical centers distributed across Italy. The PITER cohort is considered a 
representative sample of linked-to-care patients with no treatment access restrictions on the basis of 
healthcare system reimbursement criteria.
8
 PITER aims to evaluate the expected impact of DAAs on 
the natural course of hepatitis infection and on long-term morbidity and mortality in a real-life setting 
in Italy. The inclusion criteria for PITER are: all HCV-infected patients (any stage, any genotype, 
including HBV, HDV, or HIV co-infection) at least 18 years of age consecutively referred to 
outpatient clinics of the participating clinical centers during enrolment phases, who are untreated at 
the time of enrollment. The mean age of enrolled patients is 61 (range 18-94) years of age and the 
ratio of males to female is 1/1.2 (55% male).
8
 The older age of patients enrolled in PITER represents 
the cohort effect of HCV infection in Italy. Of patients enrolled in the PITER cohort in 2016, 52% 
were F0-F3, 38% F4, and 10% had decompensated cirrhosis or HCC.
8
 Treatment initiations occurring 
among enrolled patients cover the full evolution of DAA access in Italy from 2014 on.  
 
AIFA treatment data 
Real-life reported treatment data was provided from January 2015 through August 2017 by the Italian 
Medicines Agency (AIFA).
9
 AIFA reimbursement criteria included fibrosis stage ≥F2 patients, 
patients with extrahepatic manifestations in any stage of fibrosis, and liver transplant recipients, until 





Italy Polaris and PITER adjusted models  
For this analysis, two separate models were constructed. First, a Markov HCV disease 
progression model (the “Italy Polaris model”) was built using previously described 
methodology
10 
to forecast the annual prevalence of chronic HCV infection in Italy by liver 
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cases, starting in 1950, and their sex and age group distribution was back-calculated to match 
the modeled prevalence by sex and age group in 2015 to reported estimates
11
 (Supplement 
Section 1). The reported number of annual treated patients as tracked in the AIFA Monitoring 
Registry for DAAs
9
 was allocated to the age and liver disease stage of the eligible HCV-
infected population by the relative size of population in each treatment-eligible disease stage 
(Table 1). The number of annual treatments initiated within each disease stage was uniformly 
distributed across treatment-eligible ages.  
 
Afterwards, the Italy Polaris model was adapted to initiate the model in 2015 (the “PITER 
adjusted model”) with the disease stage, sex, and age group distribution of linked-to-care 
prevalent cases as reported in PITER (Supplement Section 2). Background mortality by 5-
year age and sex cohort, standard mortality ratios, and the future incident cases were applied 
as in the Italy Polaris model. The number of annual treatments initiated in this model was the 
real-life number of treatments with DAAs from 2015 to August 2017 by disease stage and 





Two general population scenarios describe the forecasted disease burden through 2030 and three 
scenarios based on PITER data evaluate the impact of linkage to care on viremic prevalence (Table 2). 
 
Scenarios – Italy Polaris Model 
Base 2016: Represents the 2016 standard of care in Italy (treatment of patients with fibrosis 
stage ≥F2) maintaining the same fibrosis stage, treatment age, and SVR rate assumptions 
through 2030. In 2016, 30,400 patients were considered to be newly linked-to-care for 
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place in Italy, the number of treated patients was expected to decrease by half by 2020 due to 
the depleting pool of eligible patients to treat.
12
 
WHO Targets: The WHO Targets scenario identifies the expansion of diagnosis and treatment 
necessary to achieve the WHO’s 2030 targets for incidence, mortality, and diagnosis coverage for 
HCV defined in the GHSS on Viral Hepatitis.
4 
 
Scenarios – PITER adjusted model 
PITER 40%, 60%, and 80% linked-to-care patients: Utilizing the PITER cohort data, three 
scenarios were created representing different assumptions regarding proportions of the 
prevalent population in 2015 being diagnosed and under care. The annual number of patients 
treated, fibrosis restrictions, ages eligible for treatment, and SVR were the same between the 
three scenarios (Table 2). In each PITER scenario, the number of patients to be treated 
annually following the year 2017 was kept constant. Under the 40% linkage-to-care scenario, 
it was assumed (given expert feedback), that 40% of the prevalent population (357,000 
patients) in Italy in 2015 was diagnosed and under care
13
. Since the exact number of patients 
linked-to-care is unknown, the same scenario was then run under the assumption of 60% 
(510,000 patients) and 80% (680,000 patients) linkage-to-care. The rationale for the 80% 
scenario was a recent study in the Italian general population
13
 and the 60% scenario was 
chosen as the midpoint.  
 
Sensitivity Analysis 
To assess the effect of uncertainties in model inputs, we used Crystal Ball, a Microsoft Excel 
(Microsoft Corporation, Redmond, WA, United States) add-in by Oracle (Oracle 
Corporation, Redwood City, CA, United States) to generate 95% uncertainty intervals on 
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Beta-PERT distributions for all uncertain inputs to estimate the impact on total viremic 
infections in 2030. The key drivers for prevalence uncertainties used in the sensitivity 
analysis are reported in the Results and Supplement Section 1. Additionally, we considered 
how the variance in prevalence affects the suggested targeted screening strategies. 
 
RESULTS 
Base 2016 (Italy Polaris Model)  
There were an estimated 849,000 (95% UI: 371,000 – 1,240,000) infected individuals in 
2015. The forecasted impact of each scenario on total number of viremic infections, HCV 
liver-related morbidity and mortality were compared through 2030 (Figure 1 and Figure 2). 
Given the relatively large number of patients treated in Italy, total infections are expected to 
decline to 288,000 (95% UI: 71,880 – 424,640), or 65%, by 2030. DC cases are forecasted to 
decrease 75% from 22,900 (95% UI: 4,300 – 46,700) in 2015 to 6,100 (95% UI: 100 – 
15,300) in 2030 (Figure 2). HCC cases are also expected to decline from 14,000 (95% UI: 
3,300 – 35,100) to 3,800 (95% UI: 60 – 12,500) by the same year. HCV liver-related 
mortality is expected to decline by 75% from 11,300 (95% UI: 2,600 – 19,600) to 3,100 (95% 
UI: 50 – 7,000) deaths by 2030. 
 
WHO Targets (Italy Polaris Model)  
In order to achieve the WHO GHSS targets, treatment was expanded to 38,000 patients 
annually by 2025; restrictions by fibrosis stage were lifted, and SVR was increased 
incrementally over the next ten years to represent the higher efficacy of treatments in coming 
years (Table 2b). Total HCV viremic infections and HCV liver related morbidity and 
mortality are expected to decline substantially, by 95%, 90%, and 90%, respectively, by 2030 
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PITER adjusted model, 40%, 60%, and 80% linked-to-care patients 
Given the 40% linkage-to-care scenario, total viremic infections would decline by 60%, to 
329,000 (95% UI: 199,960 – 365,960) patients, by 2030. However, the eligible patients to 
treat would be depleted by 2025. Under the 60% linkage-to-care scenario, the patients 
eligible for treatment would run out in 2028. Total infections were expected to decline to less 
than 260,000 (95% UI: 127,900 – 298,100) by the same year. Under the 80% linkage-to-care 
scenario, total viremic infections are forecasted to decline by 80%, from 849,000 infections to 
157,000 (95% UI: 99,380 – 196,980) by 2030. The pool of eligible patients to treat is 
expected to be depleted by 2031 (Figure1). 
 
In order to understand the age distribution of the eligible infected individuals for treatment 
and to suggest strategies to increase case finding for different linkage to care scenarios, the 
model estimates the age cohorts with the highest prevalence of asymptomatic individuals, as 
shown in Table 3. Because 30% of advanced stage liver disease (fibrosis stage ≥F3) patients 
are considered on treatment; by 2020, approximately 70% of all infected, asymptomatic (F0-
F3) individuals would be found in those born in the years 1948–1978. According to the 40% 
linked-to-care scenario, targeted screening strategies in the 1948-1978 birth cohorts could be 
implemented to sustain the current treatment rate. If 60% of the infected population are 
linked-to-care, then screening fewer birth cohorts with higher prevalence (Table 3) could be 
useful in finding at least 30% more of eligible infected F0-F3 individuals.  
 
Sensitivity Analysis 
The model inputs that had the largest contribution to the uncertainty in the Italy Polaris and PITER 
adjusted models are shown in Figure 3 (a and b). For the Italy Polaris model, the anti-HCV prevalence 
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approximately 535,000 remaining viremic cases in 2030, as compared to 288,000, if there were1.24 
million infections in 2015. More than 89% of the variability in the 2030 forecasted viremic infections 
could be explained by the estimated number of treated patients. If the eligible linked to care patients 
were to diminish and only 10,000 patients would be eligible for treatment moving forward (rather 
than the base case of 33, 700), there would be an estimated 260,000 viremic cases in 2030, almost 
100,000 more than under the base assumption. The top five factors explained more than 98% of the 
variability in both models (Figure 3a and 3b). 
 
Additionally, we assessed how prevalence may impact the different linkage-to-care scenarios and the 
related case finding strategies. Given the “low” prevalence rate, the eligible patients to treat would be 
depleted sooner than under the base case (Table 4). If prevalence was 370,000 infections rather than 
the 849,000, we would expect the eligible patients to treat to be depleted by 2022 under the 40% 
scenario; and in 2025 under both the 60% and 80% linkage to care scenarios. However, if prevalence 
was more than a million patients, the eligible patient pool would be reduced by 2027 under the 40% 
linked-to-care scenario. Under the 60 and 80% scenarios, the number of treated patients 
(approximately 35,000) could be maintained annually through 2030. The prevalence did not have a 
significant impact on the identified targeted screening strategies. Assuming a prevalence of 
approximately 370,000 cases, we estimate a less than 5% change in the distribution of F0-F3 cases by 
birth cohort.  
 
DISCUSSION 
Italy has been considered the country with the highest HCV prevalence in Western Europe, with the 
peak prevalence in older ages (>70 years).
14-16
 However, many studies estimating HCV prevalence in 
the Italian general population were conducted more than 20 years ago and have shown regional 
variances.
17
 The highest prevalence rates have been reported in Southern Italy, though many of these 
earlier studies were conducted in smaller, more rural areas. Recent studies have also reported 
decreasing rates of HCV prevalence in the country.
11,18-19
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The limitation of HCV therapy is no longer treatment efficacy or adherence, but the identification of 
available patients to treat.
20 
As with prevalence, the availability of treatment and linkage to care varies 
across the country. Though in Italy a National Hepatitis Plan exists, decentralized models of HCV 
care persist and there are no uniform strategies across regional networks. Only 2 (Sicily and Veneto) 
of 20 regions throughout Italy have developed adequate organizational and operational politics 
regarding HCV elimination.
21-23
 Linkage to care is limited in that no enhanced HCV screening and 
diagnosis is implemented in the country. The number of prescribers is restricted only to 
gastrointestinal and infectious disease specialists whom are limited per region. It was recently 
estimated that there are 1,500 residents per general practitioner in Italy, often curbing the availability 
of referral and linkage to care to a specialist.
13
 In addition, no specific strategies for marginalized 
patients and at-risk groups are implemented at the national level.  
A true cascade of care for HCV infection is lacking in Italy as the number of patients under care 
remains uncertain. Recent studies reported between 20-80% of HCV+ individuals are aware of their 
status.
11,23
 This uncertainty has clear implications for treatment, as the population first needs to be 
identified in order to be placed in care. While the real number of linked-to-care patients in Italy is 
unknown, the PITER cohort is considered a representative sample of linked-to-care patients in Italy.
8
 
The PITER linkage-to-care scenarios are based on the characteristics of patients enrolled in PITER 
and estimates different possible proportions of the ‘tip of the iceberg’. Extrapolating the age and 
fibrosis stage distribution of current linked-to-care patients (PITER model) to the general population 
in Italy (Polaris model) is useful for understanding what may occur in the overall infected population 
if current HCV trends are to remain. As seen in the Base 2016 Scenario, the WHO goal of reducing 
HCV liver-related deaths by 65% by 2030 is achievable in Italy if the treatment rate is maintained at 
current levels. However, in the 40% and 60% linkage-to-care scenarios, given the same number of 
treated patients through 2030, the eligible pool of patients to be treated would run out between 2025 
and 2028, leaving a significant proportion of infected individuals undiagnosed and without access to 
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Considering the cohort effect of HCV infection in Italy and low rates of injection drug use, the 
younger cohorts (1988+) are those with the lowest prevalence of HCV infection in Italy. We did not 
consider possible screening strategies for individuals born in 1935–1948 as the natural depletion of 
the virus in those individuals was assumed. This modelling estimates that more than 70% of the 
infected (F0–F3) individuals, those that are most often asymptomatic and undiagnosed (the 
underwater portion), were within the 1948 to 1978 birth cohorts in 2020 (Table 3). This signifies a 
potential need to increase case finding in these individuals if the treatment rate starts to decrease prior 
to the year 2025 (40% linked to care scenario). As it has been described elsewhere, though 
approximately 75% of individuals with chronic HCV in the United States are within the 1945-1965 
birth cohort, screening in this population is not systematically done and a large portion of infected 
individuals fall outside of this cohort.
24
  
If 60% of the infected population is linked-to-care then the treatment rate could be sustained until the 
year 2028. Since older individuals are more likely to already be linked-to-care, a specific increased 
case finding strategy, focusing on individuals born in years 1958–1978, could be useful in finding 
around 40% of eligible infected F0-F3 patients.  
The PITER adjusted model refers to a population with a mean age of 59 years, which in part reflects 
that of populations in other parts of the world that have similar epidemiologic characteristics (i.e., 
individuals infected previously through blood transfusion or nosocomial transmission with historical 
trends of high incidence of infection).
25
 As seen in this modelling study, the rate of treatment uptake 
will decline unless screening and linking diagnosed patients to care is improved. In the country of 
Georgia, one of the nine countries on track to achieve the WHO Targets by 2030, the number of 
newly diagnosed patients entering the national treatment program has fallen in the past year, 
suggesting that identification and linkage-to-care of HCV infected patients in the country might be 
slowing.
26,27
 The potential targeted screening strategies that were produced in this analysis are useful 
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be used for countries with different HCV epidemiology, in that it addresses the improvement of 
diagnosis and the linkage to care - key factors for achieving the elimination goals.
28,29
  
Several limitations of the analysis exist. This analysis was not focused on treatment as prevention. 
While neither disease burden model dynamically considers new infections nor reinfections in the 
population, the high treatment rate in Italy coupled with the reduced treatment restrictions exceeds the 
proportion required for treatment when compared to other dynamic models.
30-32
 Additionally, 
although the PITER  cohort is considered reasonably representative of those receiving care across the 
country, the PITER model uses a disease stage distribution based on a small proportion (9,145 of 
357,000) of diagnosed and linked-to-care patients. The true proportion of the linked-to-care 
population in Italy is unknown. While rates of up to 80% have been reported,
11
 experts involved in the 
analysis have suggested that 40% of the total infected population is linked-to-care. To address this 
uncertainty, we presented the PITER analysis under three scenarios of 40%, 60%, and 80% linkage-
to-care. Additionally, we evaluated the impact of this uncertainty and found the percent change in the 
linked-to-care population had a smaller influence on viremic prevalence in 2030 than other factors 
(Figures 2a and 2b). Lastly, the variance in prevalence had limited influence on the proportion of F0-
F3 patients identified and would not impact the screening strategies discussed. 
 
This analysis highlights that Italy is on track to meeting the WHO target of 65% reduction in liver-
related mortality by 2030. However, given the same number of annually treated patients through 
2030, the eligible pool of patients to be treated would run out between 2025 and 2028, leaving a 
significant proportion of infected individuals undiagnosed and without access to care.  Increased case 
finding through potential targeted screening strategies are necessary to achieve the WHO goals. This 
modelling analysis is a useful tool that can be used by different countries to develop screening 
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Figure 1. Total viremic infections by scenario, 2015-2030.  
The forecasted total number of viremic infections by Base 2016, PITER linkage-to-care, and 
WHO Targets scenarios were compared. By 2030, total viremic infections are expected to 
decline due to the higher treatment rate in Italy. However, the number of remaining infections 
would still remain high in each but, WHO Scenario which is forecasted to have the largest 
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Figure 2. Liver-related morbidity and mortality by scenario, 2015-2030.  
The forecasted liver related outcomes by Base 2016, and WHO Targets scenarios were 
compared. By 2030, all HCV-related outcomes are expected to decline due to the higher 
treatment rate in Italy. However, the WHO Scenario is forecasted to have the largest impact 
on liver related outcomes.  
 
Figure 3. Key drivers of uncertainty in prevalence 2030. 
Sensitivity analysis of key drivers of uncertainty in the Italy Polaris model (A) and in the 
PITER adjusted model (B) in 2030 forecasted viremic HCV prevalence (top ten shown). The 
labels refer to the high and low value of the variable under consideration. For the Italy Polaris 
model, the uncertainty in new infections considered in the model had the largest effect on the 
2030 forecast of prevalent viremic infections. The uncertainty in transition probabilities and 
standardized mortality ratio due to a history of blood transfusion (see also Supplement 
Section 1) accounted for more than 98% of all explained variation in the Italy Polaris model 
(Figure 3A). The number of treated patients explained the majority of the variability in the 
PITER model. More than 89% of the variability in the 2030 forecasted viremic infections 
could be explained by the estimated number of treated patients. The other drivers of 
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Table 1. Key inputs of the disease burden model 
Italy-Specific Parameters in Model Year Value (Range) Source 












Annual Newly Linked to Care For Treatment* 2013 30,400 Expert Input 
Annual Number Treated 2015 31,000 [9] 
*Annual Newly Linked to Care for Treatment encompasses those newly diagnosed each year.  
 
Table 2a. Inputs by scenario, 2015-2030 
 
 2015 2016 2017 2018 2019 2020+ 
Annually Treated 
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Tx: treatment; SVR: sustained virologic response 
 
Table 2b. Inputs of the WHO Targets scenario, 2015-2030 
 







































































*Annual Newly Linked to Care for Treatment encompasses those newly diagnosed each year. WHO: World Health 










This article is protected by copyright. All rights reserved. 
Table 3. Distribution of F0-F3 infected cases by birth year in the PITER and Italy 
Polaris models in 2020 
 
Birth Year Proportion of F0-F3 infected 
cases in PITER Model  
(%)* 
Proportion of F0-F3 infected cases 
in Italy Polaris Model 
(%)* 
1938-1948 28 32 
1948-1958 35 42 
1958-1968 41 26 
1968-1978 23 17 
1978-1988 10 10 
1988+ 5 8 
*Does not sum to 100% due to overlapping birth cohorts 
 
Table 4. Year the eligible pool of patients to treat is estimated to be depleted*, by 
linkage to care scenario and prevalence range 
 






           849,000 
High (n) 
1,240,000 
40% 2022 2025 2027 
60% 2025 2028 -- 
80% 2025 2031 -- 
*To assess how the uncertainty in the prevalence estimate impacts the estimated number of eligible patients to treat, the 
linkage to care scenarios were run on the range of prevalence values (low: 371,00, base: 849,000, high:1,240,000) to assess 
when the treated patients may exceed eligible patients (“be depleted”). --Signifies that given the ‘high’ prevalence estimate, 
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